Weaver Consulting Group Acquires 5,700 Shares of Fortress Biotech, Inc. (NASDAQ:FBIO)

Weaver Consulting Group raised its holdings in shares of Fortress Biotech, Inc. (NASDAQ:FBIO) by 33.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 22,998 shares of the biopharmaceutical company’s stock after acquiring an additional 5,700 shares during the quarter. Weaver Consulting Group’s holdings in Fortress Biotech were worth $47,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. PVG Asset Management Corp lifted its position in Fortress Biotech by 140.1% during the third quarter. PVG Asset Management Corp now owns 373,790 shares of the biopharmaceutical company’s stock valued at $540,000 after purchasing an additional 218,115 shares in the last quarter. Shikiar Asset Management Inc. raised its stake in shares of Fortress Biotech by 4.4% in the third quarter. Shikiar Asset Management Inc. now owns 235,969 shares of the biopharmaceutical company’s stock worth $342,000 after buying an additional 10,000 shares during the period. Geode Capital Management LLC lifted its position in shares of Fortress Biotech by 28.8% during the 3rd quarter. Geode Capital Management LLC now owns 168,607 shares of the biopharmaceutical company’s stock valued at $244,000 after buying an additional 37,736 shares in the last quarter. B. Riley Wealth Advisors Inc. purchased a new position in shares of Fortress Biotech during the 2nd quarter valued at about $207,000. Finally, Atria Investments Inc grew its stake in shares of Fortress Biotech by 58.4% during the 3rd quarter. Atria Investments Inc now owns 71,484 shares of the biopharmaceutical company’s stock valued at $103,000 after acquiring an additional 26,351 shares during the period. Institutional investors own 96.51% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on FBIO shares. HC Wainwright lifted their price target on shares of Fortress Biotech from $24.00 to $26.00 and gave the company a “buy” rating in a report on Monday, November 18th. StockNews.com downgraded shares of Fortress Biotech from a “hold” rating to a “sell” rating in a research report on Friday, November 15th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $13.67.

Fortress Biotech Trading Down 4.9 %

Shares of FBIO opened at $2.15 on Wednesday. The business’s 50 day moving average is $1.89 and its 200 day moving average is $1.86. Fortress Biotech, Inc. has a 12-month low of $1.36 and a 12-month high of $2.89. The company has a market capitalization of $59.35 million, a PE ratio of -0.70 and a beta of 1.67.

Fortress Biotech Profile

Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.